Search
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalThis drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeFlorbetaben F-18
go.drugbank.com/drugs/DB09148ApprovedInvestigationalFlorbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaqu...
Protein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalIt is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation.
Human interferon beta
go.drugbank.com/drugs/DB14999ApprovedInvestigational[L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).
Almotriptan
go.drugbank.com/drugs/DB00918ApprovedIt works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: ALMOTRIPTAN DOC GENERICILevofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigational(i.e. it does not invert to the inactive isomer). … [A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration
Products: CRAVIT OPHTHALMIC SOLUTION 1.5% w/v, CRAVIT OPHTHALMIC SOLUTION 0.5% w/vSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTrefoil Factor 2
go.drugbank.com/drugs/DB15750ExperimentalThe trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins.
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalThe treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. … Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigationalSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although mult...